Summary
In vitro antibacterial activity of the new fluoroquinolone CI-960 was tested against 139 strains of Brucella melitensis, isolated from 138 patients in a major tertiary care referral centre. Seven percent of the strains were inhibited by 0.06 mg/L and 99% by 0.12 mg/L of CI-960. Five other fluoroquinolones tested had comparable or slightly higher minimum inhibitory concentration values, inhibiting the growth of 138 of the 139 isolates at 0.25 to 0.5 mg/L One isolate, which had previously developed resistance during ciprofloxacin therapy, showed cross-resistance to CI-960 and other fluoroquinolones.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Al Sibai MV, Qadri SMH. Development of ciprofloxacin resistance in Brucella melitensis. Journal of Antimicrobial Chemotherapy 25: 302–303, 1990
Bosch J, Linares J, Lopez de Goicoencheh MJ, Ariza J, Cisnal MC, et al. In vitro activity of ciprofloxacin, ceftriaxone and five other antimicrobial agents against 95 strains of Brucella melitensis. Journal of Antimicrobial Chemotherapy 17: 459–461, 1986
Buchanan TM, Faber LC, Feldman RA. Brucellosis in the United States, 1960-1972. An abattoir-associated disease. Part 1. Clinical features & therapy. Medicine 53: 403–413, 1974
Easmon CSF, Crane JP. Uptake of ciprofloxacin by human neutrophils. Journal of Antimicrobial Chemotherapy 16: 67–73, 1985
FAO/WHO Expert Committee of Brucellosis (1986). Sixth Report, Technical Report Series 740. World Health Organization, Geneva, 1986
Farrell ID, Hinchutte PM, Robertson L. Sensitivity of Brucella spp. to tetracycline and its analogues. Journal of Clinical Pathology 29: 1097–1099, 1976
Gobernado M, Canton E, Santos M. In-vitro activity of ciprofloxacin and other 4-quinolones against Brucella melitensis. Proceeding of the First International Ciprofloxacin Workshop, p. 30, Leverkusen 1985
Haddad Q, Smith SR. Current experience with brucellosis at Security Forces Hospital, Riyadh. Annals of Saudi Medicine 6: S11–S14, 1986
Hall WE, Marion RE. In-vitro susceptibility of Brucella to various antibiotics. Applied Microbiology 20: 600, 1970
Hausler WJ, Mayer NP, Holcomb LA. Brucella. In Lennette et al. (Eds) Manual of clinical microbiology, pp. 382–386, American Society for Microbiology, Washington DC, 1985
Hudson SJ, Ingham HR, Snow MH. Treatment of Salmonella typhi carrier state with ciprofloxacin. Lancet 1: 1047, 1985
Madkour MM. Brucellosis, pp. 12–14, Butterworths, London, 1989
Qadri SMH, Akhtar M, Ueno Y, Al-Sabai MB. Susceptibility of Brucella melitensis to fluoroquinolones. Drugs in Experimental Clinical Research 15: 483–485, 1989
Qadri SMH, Al-Sedairy S, Ueno Y. Antibacterial activity of lo-mefloxacin against Brucella melitensis. Diagnostic Microbiology and Infectious Disease 13: 277–279, 1990
Rizzo-Naudi J, Griseti-Soler N, Canado W. Human brucellosis. An evaluation of antibiotics in the treatment of brucellosis. Postgraduate Medical Journal 13: 520–525, 1967
Sanchez JP, Domagala JM, Hagen SE, et al. Quinolone antibacterial agents. Synthesis and structure-activity relationships of 8-substituted quinolone-3-carboxylic acids and 1,8-naphthyri-dine-3-carboxylic acids. Journal of Medicinal Chemistry 31: 983–991, 1988
Schoenknecht FD, Sabath LD, Thornberry C. Susceptibility tests: special tests. In Lennette et al. (Eds) Manual of clinical microbiology. American Society for Microbiology pp. 1000–1008, Washington DC, 1985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Qadri, S.M.H., Ueno, Y. Susceptibility of Brucella melitensis to the New Fluoroquinolone CI-960. Drug Invest. 3, 365–367 (1991). https://doi.org/10.1007/BF03259754
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03259754